Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is enhanced when ch14.18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2. We conducted a study to determine whether adding ch14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk neuroblastoma. METHODS: Patients with high-risk neuroblastoma who had a response to induction therapy and stem-cell transplantation were randomly assigned, in a 1:1 ratio, to receive standard therapy (six cycles of isotretinoin) or immunotherapy (six cycles of isotretinoin and five concomitant cycles of ch14.18 in combination with alternating GM-CSF and interleukin-2). Event-free survival and overall survival were compared between the immunotherapy group and the standard-therapy group, on an intention-to-treat basis. RESULTS: A total of 226 eligible patients were randomly assigned to a treatment group. In the immunotherapy group, a total of 52% of patients had pain of grade 3, 4, or 5, and 23% and 25% of patients had capillary leak syndrome and hypersensitivity reactions, respectively. With 61% of the number of expected events observed, the study met the criteria for early stopping owing to efficacy. The median duration of follow-up was 2.1 years. Immunotherapy was superior to standard therapy with regard to rates of event-free survival (66±5% vs. 46±5% at 2 years, P=0.01) and overall survival (86±4% vs. 75±5% at 2 years, P=0.02 without adjustment for interim analyses). CONCLUSIONS: Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the National Institutes of Health and the Food and Drug Administration; ClinicalTrials.gov number, NCT00026312.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some immunotherapies have shown promise in this setting, such as dinutuximab administered in combination with cytotoxic therapy in relapsed/refractory neuroblastoma3,4.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 1×
“Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Maris, J. M., Hogarty, M. D., Bagatell, R., & Cohn, S. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60983-0 · Cited by 2,032
Self-citationMatthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898 · cited 2×
“Hypersensitivity reaction 14 (10) 33 (26) 6 (5) 29 (25) 13 (12) 3 (3)”
Self-citationWeng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · cited 1×
“Complete response 38 (34) 40 (35) 78 (35) 61±7 86±5”
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Matthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H., Adkins, E. S., Haas-Kogan, D., Gerbing, R. B., London, W. B., & Villablanca, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8925 · Cited by 858 · cited 1×
“Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
Self-citationAdoptive cell therapy for the treatment of patients with metastatic melanoma
Rosenberg, S. A., & Dudley, M. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.002 · Cited by 595
Research works printed but not linked: 10
- Schulz G, 1984, Cancer Res, 44, 5914
- Yu AL, 1997, Proc Am Soc Oncol, 6, 1846
- Barker E, 1991, Cancer Res, 51, 144
- Albertini MR, 1997, Clin Cancer Res, 3, 1277
- Hank JA, 1990, Cancer Res, 50, 5234
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Greenwood M, 1926, Rep Public Health Med Subj (Lond), 33, 1
- Barker E, 1993, Cancer Res, 53, 362
- Dallegri F, 1989, Clin Exp Immunol, 77, 58
- Simon T, 2009, Pediatr Blood Cancer, 53, 708
Cited by
Items 901–1,000 of 1,000
Sánchez-Molina, S., Figuerola-Bou, E., Sánchez‐Margalet, V., de la Cruz‐Merino, L., Mora, J., de Álava, E., García-Domínguez, D. J., & Hontecillas‐Prieto, L. (2022) · Cancers · doi:10.3390/cancers14215473 · Cited by 16
“GD2-specific CAR T-cells were highly effective in patients with high-risk neuroblastoma [99], although no antitumor effect against GD2-positive EWS xenograft models was reported.”
BackgroundCabral, J., Fernandez, E. I., Toy, B., & Secola, R. (2022) · Pediatric Drugs · doi:10.1007/s40272-022-00544-9 · Cited by 14
“Patients should be closely monitored for signs of IRRs, such as cough, bronchospasm, hypoxia, angioedema, anaphylaxis, pruritus, and urticaria [3, 9, 10, 12, 24].”
BackgroundInfluentialVaro, A., Castañeda, A., Chamorro, S., Muñoz, J. P., Gorostegui, M., Celma, M. S., López, S., Simão, M., Pérez‐Jaume, S., & Mora, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1164949 · Cited by 14
Lodewijk, I., Dueñas, M., Paramio, J. M., & Rubio, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1272681 · Cited by 16
“In 2010, Yu et al. (179) reported a signi fi cant increase in event-free survival and overall survival for high-risk neuroblastoma patients treated with a combination of anti-GD2 mAb ch14.”
BackgroundTrautwein, N. F., Schwenck, J., Seitz, C. M., Seith, F., Calderón, E., von Beschwitz, S., Singer, S., Reischl, G., Handgretinger, R., Schäfer, J. F., et al. (2024) · Theranostics · doi:10.7150/thno.92481 · Cited by 16
“…against GD2, revealed a significant benefit in addition to standard therapy with retinoids improving overall survival in patients with high-risk neuroblastoma [10] and consecutively obtained a registered indication for maintenance therapy by the U.S. Food and Drug Administration (FDA) [11].”
BackgroundLange, B. J., Yang, R. K., Gan, J., Hank, J. A., Sievers, E. L., Alonzo, T. A., Gerbing, R. B., & Sondel, P. M. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.22966 · Cited by 14
Self-citationPortwine, C., Rae, C. S., Davis, J. H., Teira, P., Schechter, T., Lewis, V. A., Mitchell, D., Wall, D. A., Pullenayegum, E., & Barr, R. D. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26063 · Cited by 14
“Several studies by other investigators have confirmed the survival advantage provided by HSCT, while a further advantage has been gained with the addition of immunotherapy, achieving a 2-year OS exceeding 85%.[3] There is a lack of knowledge regarding whether the cost of survival, in terms of health-related quality of…”
BackgroundMethodStrategies for Bispecific Single Chain Antibody in Cancer Immunotherapy
Zhou, S., Wei, J., Su, S., Chen, F., Qiu, Y., & Liu, B. (2017) · Journal of Cancer · doi:10.7150/jca.19501 · Cited by 16
“GD2 CD3 / Neuroblastoma, melanoma ovarian carcinoma Preclinical [71, 72]”
BackgroundLucas, J. T., McCarville, M. B., Cooper, D. A., Doubrovin, M., Wakefield, D. V., Santiago, T., Li, Y., Li, X., Krasin, M. J., Santana, V. M., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.11.041 · Cited by 14
Giwa, A. O., Fatai, A. A., Gamieldien, J., Christoffels, A. G., & Bendou, H. (2020) · Oncotarget · doi:10.18632/oncotarget.27808 · Cited by 15
“Patients classified in low-risk groups have good outcomes contrary to high-risk groups who present poor outcomes despite extensive therapies [4] and with a disproportionate number dying or suffering profound treatment related morbidities [7, 8].”
BackgroundZhang, Y., Kupferschläger, J., Lang, P., Reischl, G., Handgretinger, R., la Fougère, C., & Dittmann, H. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.261854 · Cited by 15
Inflammation: What role in pediatric cancer?
Morgenstern, D. A., & Anderson, J. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.24008 · Cited by 16
“The recently reported success of antibody therapy targeting GD2 for the treatment of high-risk neuroblastoma [88,89] provides encouragement for the validity of these approaches, yet our understanding of the mode of action and interactions with the pre-existing tumor immune environment remains poor.”
BackgroundNeuroblastoma in Africa: A Survey by the Franco-African Pediatric Oncology Group
Traoré, F., Eshun, F., Togo, B., Yao, J. J. A., & Lukamba, R. M. (2016) · Journal of Global Oncology · doi:10.1200/jgo.2015.001214 · Cited by 17
“MYCN-amplified tumors are generally considered high risk and are treated intensively with induction chemotherapy, surgical resection of primary tumor, autologous stem-cell transplantation, involved-field radiation, andmaintenance therapy with 13-cis-retinoic acid either alone or in combination with cytokines and anti-…”
BackgroundStreby, K. A., Parisi, M. T., Shulkin, B. L., LaBarre, B., Bagatell, R., Diller, L., Grupp, S. A., Matthay, K. K., Voss, S. D., Yu, A. L.-T., et al. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30418 · Cited by 15
Self-citationCupit-Link, M., & Federico, S. M. (2023) · Cancers · doi:10.3390/cancers15184609 · Cited by 13
“All other patients received post-Consolidation therapy as per ANBL0032 [9,10].”
Immune Microenvironment in Childhood Cancers: Characteristics and Therapeutic Challenges
Pathania, A. S. (2024) · Cancers · doi:10.3390/cancers16122201 · Cited by 18
“18 (dinutuximab) with GM-CSF and IL-2 could improve survival rates among children with high-risk neu-Cancers roblastoma [177].”
BackgroundHigh-Risk Neuroblastoma Challenges and Opportunities for Antibody-Based Cellular Immunotherapy
Persaud, N. V., Park, J. A., & Cheung, N. V. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164765 · Cited by 13
“18-K322A, respectively, engaging NK cells and myeloid effector cells in antibody-dependent cell cytotoxicity (ADCC), while activating complement-dependent cytotoxicity (CDC) [53].”
BackgroundAsymmetric N-Glycosylation in the Tailpiece of Recombinant IgA1
Peris‐Díaz, M. D., Deslignière, E., Jager, S., Mokiem, N. J., Barendregt, A., Bondt, A., & Heck, A. J. R. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c13156 · Cited by 13
Flaadt, T., Rehm, J., Simon, T., Hero, B., Ladenstein, R. L., Lode, H. N., Grabow, D., Nolte, S., Crazzolara, R., Greil, J., et al. (2025) · Cancers · doi:10.3390/cancers17010149 · Cited by 16
Tian, G., Courtney, A. N., Yu, H., Bhar, S., Xu, X. Y., Barragán, G. A., Martínez-Amador, C., Ghatwai, N., Wood, M. S., Schady, D. A., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010156 · Cited by 13
Emerging clinical and research approaches in targeted therapies for high-risk neuroblastoma
AlKhazal, A., Chohan, S., Ross, D. J., Kim, J., & Brown, E. G. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1553511 · Cited by 17
“18; Unituxin), were the fi rst immunotherapy approved for use in HRNB. Dinutuximab a murine-chimeric mAb, binds to GD2, triggering the binding of C1q and initiating complement-dependent cytotoxicity (CDC) (56).”
Henderson, T. O., Bardwell, J. K., Kao, P., Nathan, P. C., Landier, W., Mostoufi‐Moab, S., Brinkman, T. M., Schulte, F., Park, J. R., Armenian, S. H., et al. (2025) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(25)00241-x · Cited by 16
Self-citationTargeting Human Cancer Stem Cells with Monoclonal Antibodies
Naujokat, C. (2012) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.s5-007 · Cited by 15
Ophthalmic Implications of Chimeric Antigen Receptor T-Cell Therapy
Chodnicki, K. D., & Prasad, S. (2021) · Seminars in Ophthalmology · doi:10.1080/08820538.2021.1897857 · Cited by 14
“Immunotherapy with anti-GD2 antibodies has shown promise in treating patients with another neuroectodermal tumor, high-risk neuroblastoma, validating GD2 as a possible target.(14) The other target focus, CD171 (also known as L1 cell adhesion molecule), is a transmembrane glycoprotein and is involved in neuronal cell p…”
BackgroundExploring and Targeting the Tumor Immune Microenvironment of Neuroblastoma
Masih, K. E., Wei, J., Milewski, D., & Khan, J. M. (2021) · Journal of Cellular Immunology · doi:10.33696/immunology.3.111 · Cited by 19
“More recently, immunotherapeutic approaches, utilizing monoclonal antibodies targeting GD2, combined with IL-2, GM-CSF, and isotretinoin, have demonstrated improved survival in the high-risk patient population [8,9].”
BackgroundCardiovascular disease and chimeric antigen receptor cellular therapy
Rao, A., Stewart, A. F., Eljalby, M., Ramakrishnan, P., Anderson, L. D., Awan, F. T., Chandra, A., Vallabhaneni, S., Zhang, K., & Zaha, V. G. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.932347 · Cited by 13
Inagaki, F. F., Kato, T., Furusawa, A., Okada, R., Wakiyama, H., Furumoto, H., Okuyama, S., Choyke, P. L., & Kobayashi, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102037 · Cited by 13
“This drug was tested in combination with interleukin-2 (IL-2), granulocyte-macrophage colony-stimulating factor (GM-CSF), and 13-cis retinoic acid (RA) [9].”
MethodPain mitigation and management strategies for anti‐GD2 infusions: An expert consensus
Nysom, K., Gomez-Morad, A. D., Rafael, M., Zier, J. L., Marachelian, A., Watt, T. C., & Morgenstern, D. A. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30217 · Cited by 13
Vaccine-based clinical trials in ovarian cancer
Leffers, N., Daemen, T., Boezen, H. M., Melief, C. J. M., & Nijman, H. W. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.42 · Cited by 13
Lee, J. W., Kang, E., Sung, K. W., Yi, E. S., Lee, S. H., Yoo, K. H., & Koo, H. H. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26399 · Cited by 15
Riccardo, F., Réal, A., Voena, C., Chiarle, R., Cavallo, F., & Barutello, G. (2017) · Vaccines · doi:10.3390/vaccines5030020 · Cited by 15
“Immunotherapy approaches that have recently shown increasing promise in the field of adulthood cancer therapy seem to be viable options for improving the treatment of childhood cancer by means of chimeric monoclonal antibodies [179,180], chimeric antigen receptor T cells [181–184], and cancer vaccines [185–187].”
BackgroundPursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors
Bellantoni, A. J., & Wagner, L. M. (2021) · Cancers · doi:10.3390/cancers13143531 · Cited by 14
General Strategies for Glycan Microarray Data Processing and Analysis
Temme, J. S., & Gildersleeve, J. C. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2148-6_5 · Cited by 13
Stagno, M. J., Schmidt, A., Bochem, J., Urla, C., Handgretinger, R., Stanchi, K. M. C., Saup, R., Queudeville, M., Fuchs, J., Warmann, S. W., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01855-x · Cited by 13
“This is in agreement with previous immunohistochemical studies, which showed that GD2 has a high level of expression in NB patients [40, 50].”
BackgroundResultWillems, L., Waer, M., & Billiau, A. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25169 · Cited by 13
Nassin, M. L., Perizes, E. N., Gurbuxani, S. K., Cohn, S. L., Cunningham, J. M., & LaBelle, J. L. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.11.012 · Cited by 13
“Increased survival has been gained in these patients with the addition of post-transplant dinutuximab, (chimeric antiGD2 monoclonal antibody) plus cytokines and isotretinoin [7].”
BackgroundSelf-citationPennington, B., Ren, S., Barton, S., Bacelar, M., & Edwards, S. J. (2018) · PharmacoEconomics · doi:10.1007/s40273-018-0744-0 · Cited by 13
Shi, J. P., Yu, Y., Jin, Y., Lu, J., Zhang, J., Wang, H., Han, W., Chu, P., Tai, J., Chen, F., et al. (2019) · Journal of Cancer · doi:10.7150/jca.26719 · Cited by 13
“Although advanced immunotherapy and multiple cytotoxic therapies are applied, the survival rate of high-risk NB remains below 50% [4, 5].”
BackgroundUssowicz, M., Wieczorek, A., Dłużniewska, A., Pieczonka, A., Dębski, R., Drabko, K. A., Goździk, J., Balwierz, W. A., Handkiewicz-Junak, D., & Wachowiak, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.647361 · Cited by 14
“Immune therapy with dinutuximab or dinutuximab beta is associated with the most important recent treatment improvement in neuroblastoma, but it has not been studied in patients undergoing the MIBG therapy (31, 32).”
BackgroundEssentially all models are wrong, but some are useful
Simard, J. M. (2015) · Neurology · doi:10.1212/wnl.0000000000001769 · Cited by 13
Enrollment in Clinical Cancer Trials
Dodgshun, A. J., Silva, M. P. D., Bradbeer, P., & Cross, S. F. (2014) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000123 · Cited by 12
“Physician decision: treatment 8 (4) Technical 7 (3) Physician decision: compliance 6 (3) Emergency treatment 3 (1) Administrative decision 1 (0) Breach of protocol 1 (0)”
BackgroundDeveloping immunotherapies for childhood cancer
Capsomidis, A., & Anderson, J. (2016) · Archives of Disease in Childhood Education & Practice · doi:10.1136/archdischild-2016-311284 · Cited by 12
Bates, P. D., Rakhmilevich, A. L., Cho, M. M., Bouchlaka, M. N., Rao, S. L., Hales, J. M., Orentas, R. J., Fry, T. J., Gilles, S. D., Sondel, P. M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.668307 · Cited by 12
“To determine the contribution of NK alloreactivity to a GVT effect without contribution of donor T cells, we designed a F1 into parent allogeneic HSCT model so that (1) any residual donor T cells in the BM graft would be tolerized to host MHC and minor histocompatibility antigens in the thymus and thus not mediate GVH…”
BackgroundSelf-citationLascano, D., Zobel, M. J., Lee, W. G., Chen, S., Zamora, A. K., Asuelime, G. E., Choi, S. Y., Chronopoulos, A., Asgharzadeh, S., Marachelian, A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-46968-2 · Cited by 13
GD2 in Breast Cancer: A Potential Biomarker and Therapeutic Target
Mokbel, K. (2024) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20471 · Cited by 12
Shakeel, A., Baloch, A., Kumari, V., Kazmi, S. K. Z., Aftab, K., Abid, S., Syed, A., Yousuf, J., Hasanain, M., Anjum, M. U., et al. (2024) · Medicine · doi:10.1097/md.0000000000040662 · Cited by 12
Simon, T., Thole-Kliesch, T. M., Castelli, S., Timmermann, B., Jazmati, D., Schwarz, R., Fuchs, J., Warmann, S. W., Hubertus, J., Schmidt, M. C., et al. (2025) · Klinische Pädiatrie · doi:10.1055/a-2556-4302 · Cited by 14
“…survival benefit for patients who underwent immunotherapy [218], the combination of dinutuximab, granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 2 (IL2) and isotretinoin is considered standard of care in the USA for first-line high-risk neuroblastoma treatment [217].”
DeSantes, K. B., McDowell, K. A., Sondel, P. M., Hutson, P. R., Kaplan, R. N., Park, J. R., Hegde, M. G., Mackall, C. L., & Maris, J. M. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0293 · Cited by 18
“Indeed, this was the approach that led to FDA approval of dinu-tuximab for the treatment of high-risk neuroblastoma (32).”
Self-citationFernández-Rilo, A. C., de Billy, E., Baldo, G. D., Angelis, B. D., Rossi, S., Bufalo, F. D., Quintarelli, C., Locatelli, F., Mastronuzzi, A., & Vinci, M. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01079-1 · Cited by 14
“Nevertheless, a notable proportion of patients still experience relapses, and the mechanisms underlying resistance, as well as the possibility of the occurrence of antigen escape to anti-GD2, remain poorly elucidated 126 – 128 .”
The Current Landscape of Modular CAR T Cells
Joechner, A. H., Mach, M., & Li, Z. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262411898 · Cited by 14
“…OT-OT risks by healthy tissue’s antigen expression: GD2 in peripheral nerves can cause severe neuropathic pain and requires analgesic medication [108]; HER2 expression in lung epithelium confers a risk of pulmonary toxicity, including fatal events [109]; whereas B7-H3 is broadly expressed on…”
Jin, Y., Wang, H., Han, W., Lu, J., Chu, P., Han, S., Ni, X., Ning, B., Yu, D., & Guo, Y. (2015) · Tumor Biology · doi:10.1007/s13277-015-4192-6 · Cited by 12
“The survival rate for the most aggressive subset of NB remains approximately 50%, despite the application of intensive multimodal cytotoxic therapy and recent advances in immunotherapy [2, 3].”
BackgroundSevere COVID‐19 infection in a child receiving immunotherapy for cancer
Smith, V. R., Whittle, S. B., Coleman, R. D., Muñoz, F. M., de Guzman, M. M., Foster, J. H., & Navai, S. A. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28710 · Cited by 12
Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma
Schultz, C. R., Swanson, M. A., Dowling, T. C., & Bachmann, A. S. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04309-y · Cited by 12
Manji, A., Samson, Y., Deyell, R. J., Johnston, D. L., Lewis, V. A., Zorzi, A. P., Berman, J. N., Brodeur‐Robb, K., Morrison, E. M., Kee, L., et al. (2022) · Cancers · doi:10.3390/cancers14122985 · Cited by 12
“Experience with maintenance therapy in pediatric solid tumors, however, has been largely limited to immunotherapy and retinoic acid in neuroblastoma [2], and vinorelbine and cyclophosphamide in rhabdomyosarcoma [3].”
BackgroundMetastasis in neuroblastoma: the MYCN question
Bhavsar, S. P. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1196861 · Cited by 12
Lode, H. N., Ladenstein, R. L., Troschke‐Meurer, S., Struppe, L., Siebert, N., Zumpe, M., Ehlert, K., Huber, S., Glogova, E., Hundsdoerfer, P., et al. (2023) · Cancers · doi:10.3390/cancers15133364 · Cited by 12
“When used in the maintenance phase, the anti-GD2 antibody dinutuximab in combination with interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF), or dinutuximab beta without additional cytokine comedication, increased EFS at 5 years by ~15% [3,7].”
MethodEnhancing IgA-mediated neutrophil cytotoxicity against neuroblastoma by CD47 blockade
Chan, C., Stip, M. C., Nederend, M., Jansen, M., Passchier, E. M., van den Ham, F., Wienke, J., van Tetering, G., & Leusen, J. H. W. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008478 · Cited by 12
Ziebarth, A., Felder, M. A. R., Harter, J. M., & Connor, J. P. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1267-8 · Cited by 12
“undergoing immunotherapy had grade 3 or higher pain, 23 % had capillary leak syndrome and 25 % had hypersensitivity reactions [14].”
BackgroundInterleukin 2 plus anti-GD2 immunotherapy: helpful or harmful?
Matthay, K. K. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30627-2 · Cited by 12
Self-citationBone Marrow Environment in Metastatic Neuroblastoma
Brignole, C., Pastorino, F., Perri, P., Amoroso, L., Bensa, V., Calarco, E., Ponzoni, M., & Corrias, M. V. (2021) · Cancers · doi:10.3390/cancers13102467 · Cited by 12
“Finally, BM MSC can also affect response to anti-GD2 immunotherapy, nowadays included in the standard of care for children with stage M NB [86,87].”
BackgroundBalyasny, S., Lee, S. M., Desai, A. V., Volchenboum, S. L., Naranjo, A. H., Park, J. R., London, W. B., Cohn, S. L., & Applebaum, M. A. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.16248 · Cited by 12
Self-citationNeuroblastoma xenograft models demonstrate the therapeutic potential of 177Lu-octreotate
Romiani, A., Spetz, J. K. E., Shubbar, E., Lind, D. E., Hallberg, B., Palmer, R. H., & Forssell-Aronsson, E. B. (2021) · BMC Cancer · doi:10.1186/s12885-021-08551-8 · Cited by 13
“Immunotherapy with dinutuximab in combination with granulocytemacrophage colony-stimulating factor, interleukin-2 and isotretinoin was compared to treatment with isotretinoin for HR-NB patients and resulted to a 2-year EFS of 66 and 46%, respectively [15].”
MethodBispecific antibodies for the treatment of neuroblastoma
Espinosa-Cotton, M. M., & Cheung, N. V. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108241 · Cited by 14
“18, (Yu, Gilman et al. 2010) and long-term survival was less than 50% .”
Immunotherapy for Pediatric Brain and Spine Tumors: Current State and Future Directions
Estévez-Ordoñez, D., Gary, S. E., Atchley, T. J., Maleknia, P. D., George, J. A., Laskay, N. M. B., Gross, E. G., Devulapalli, R. K., & Johnston, J. M. (2022) · Pediatric Neurosurgery · doi:10.1159/000528792 · Cited by 12
“Yu et al. [61] further showed the improved event-free and overall survival in children with HRNB receiving this combination therapy which eventually led to the FDA approval of anti-GD2 antibody and cytokine immunotherapies such as dinutuximab and naxitamab-gqgk for the treatment of HRNB [61, 62].”
BackgroundCeppi, F., Popovic, M. B., Bourquin, J., & Renella, R. (2017) · European Journal of Pediatrics · doi:10.1007/s00431-017-2982-0 · Cited by 12
The State of Cellular Adoptive Immunotherapy for Neuroblastoma and Other Pediatric Solid Tumors
Le, T.-P., & Thai, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01640 · Cited by 13
Immunotherapy for Neuroblastoma
Kudva, A., & Modak, S. I. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812005-7.00009-6 · Cited by 14
Maniwa, J., Fumino, S., Kimura, K., Tanaka, T., Higashi, M., Kishida, T., Mazda, O., & Tajiri, T. (2019) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2019.08.023 · Cited by 12
Immune-Based Approaches for the Treatment of Pediatric Malignancies
Bosse, K. R., Majzner, R. G., Mackall, C. L., & Maris, J. M. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033436 · Cited by 15
Self-citationLiebscher, L., Weißenborn, C., Langwisch, S., Gohlke, B.-O., Preißner, R., Rabinovich, G. A., Christiansen, N. M., Christiansen, H., Zenclussen, A. C., & Fest, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.020 · Cited by 12
Baliga, S., & Yock, T. I. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.08.021 · Cited by 12
Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours
Seiboldt, T., Zeiser, C., Nguyen, D., Çelikyürekli, S., Herter, S., Najafi, S., Stroh-Dege, A., Meulenbroeks, C., Mack, N. L., Salem-Altintas, R., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02740-5 · Cited by 11
Prospects of anti-GD2 immunotherapy for retinoblastoma
Zhang, X., You, W., Wang, Y., Dejenie, R., Wang, C., Huang, Y., & Li, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1499700 · Cited by 16
Kendsersky, N. M., Odrobina, M., Mabe, N. W., Farrel, A., Grossmann, L. D., Tsang, M., Groff, D., Wolpaw, A. J., Narch, A., Zammarchi, F., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf012 · Cited by 12
Self-citationNew Targets and Targeted Drugs for the Treatment of Cancer: An Outlook to Pediatric Oncology
Rössig, C., Juergens, H., & Berdel, W. E. (2011) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2011.613094 · Cited by 12
“Anti-GD2 antibodies have shown clinical activity in refractory disease and have entered randomized trials [70].”
BackgroundNew Molecular and Cellular Mechanisms of Tolerance: Tolerogenic Actions of IL-2
Pérol, L., & Piaggio, E. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3139-2_2 · Cited by 11
Hu, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.655554 · Cited by 12
“Our original hypothesis is that IL-10 plus 228 anti-GD2 antibody may activate an NK cell ADCC to kill cancer cells(6).”
BackgroundMethodAdvances in pharmacotherapy for neuroblastoma
Pezeshki, P. S., Moeinafshar, A., Ghaemdoust, F., Razi, S., Keshavarz‐Fathi, M., & Rezaei, N. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1953470 · Cited by 11
“toma patients with minimal residual disease [14].”
BackgroundMethodAdvances in liquid biopsy in neuroblastoma
Zhuo, Z., Lin, L., Miao, L., Li, M., & He, J. (2022) · Fundamental Research · doi:10.1016/j.fmre.2022.08.005 · Cited by 12
Whole exome sequencing of high-risk neuroblastoma identifies novel non-synonymous variants
Przybyła, W., Paulsen, K. M. G., Mishra, C. K., Nygård, S., Engebretsen, S., Ruud, E., Trøen, G., Beiske, K., & Baumbusch, L. O. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273280 · Cited by 11
“by infusing monoclonal antibodies against the tumor-associated disialoganglioside GD2, combined with for example granulocyte–macrophage colony-stimulating factor and interleukin-2 [53].”
BackgroundMallhi, K. K., Lum, L. G., Schultz, K. R., & Yankelevich, M. (2014) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.10.001 · Cited by 12
Nanomedicine as an innovative therapeutic strategy for pediatric cancer
Aleassa, E. M., Xing, M. M. Q., & Keijzer, R. (2015) · Pediatric Surgery International · doi:10.1007/s00383-015-3683-2 · Cited by 11
New Immunotherapeutic Strategies for the Treatment of Neuroblastoma
Croce, M., Corrias, M. V., Rigo, V., & Ferrini, S. (2015) · Immunotherapy · doi:10.2217/imt.14.117 · Cited by 14
New Strategies in Sarcoma Therapy: Linking Biology and Novel Agents
Janeway, K. A., & Maki, R. G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0875 · Cited by 11
“18 significantly improves event free and overall survival (7).”
BackgroundDesai, A. V., Seif, A. E., Li, Y., Getz, K., Fisher, B. T., Huang, V., Mante, A., Aplenc, R., & Bagatell, R. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.25893 · Cited by 11
Downregulation of c-Myc is involved in TLR3-mediated tumor death of neuroblastoma xenografts
Lin, L., Huang, C., Wu, C.-L., Wu, M., Hsu, W., & Chuang, J. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2016.57 · Cited by 14
Nivolumab in paediatric cancer: children are not little adults
Mora, J., & Modak, S. I. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30086-3 · Cited by 11
Bishop, M. W., Hutson, P. R., Hank, J. A., Sondel, P. M., Furman, W. L., Meagher, M. M., Navid, F., & Santana, V. M. (2020) · mAbs · doi:10.1080/19420862.2020.1773751 · Cited by 11
“Treatment of children with high-risk neuroblastoma now incorporates the use of agents targeting disialoganglioside GD2, a surface molecule uniformly expressed on most neuroblasts, resulting in improved survival rates.(1) Currently, the chimeric monoclonal antibody dinutuximab (ch14.”
BackgroundSelf-citationSiebert, N., Zumpe, M., von Lojewski, L., Troschke‐Meurer, S., Marx, M., & Lode, H. N. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1836768 · Cited by 11
“To increase ADCC, IL-2, and GM-CSF were included in treatment protocols.(2,7) However, treatment of high-risk NB patients with the anti-GD2 Ab ch14.”
MethodGartrell, J., Shulkin, B. L., Helmig, S. E., Caldwell, K. J., Furman, W. L., & Federico, S. M. (2020) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001992 · Cited by 11
Rovigatti, U. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.044 · Cited by 12
CD146 is a potential immunotarget for neuroblastoma
Obu, S., Umeda, K., Ueno, H., Sonoda, M., Tasaka, K., Ogata, H., Kouzuki, K., Nodomi, S., Saida, S., Kato, I., et al. (2021) · Cancer Science · doi:10.1111/cas.15124 · Cited by 12
Krytska, K., Casey, C. E., Pogoriler, J. E., Martínez, D., Rathi, K. S., Farrel, A., Berko, E. R., Tsang, M., Sano, R. R., Kendsersky, N. M., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0137 · Cited by 11
“While a randomized phase III study showed a 10% improvement in relapse-free survival, the therapy is toxic, and relapses occur on or after therapy (3, 4).”
BackgroundSelf-citationHorwacik, I., & Rokita, H. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3959 · Cited by 11
Precision oncology: A primer for pediatric surgeons from the APSA cancer committee
Harris, C. J., Waters, A. M., Tracy, E. T., Christison-Lagay, E. R., Baertschiger, R. M., Ehrlich, P. F., Abdessalam, S. F., Aldrink, J. H., Rhee, D. S., Dasgupta, R. A., et al. (2019) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2019.10.017 · Cited by 11
Feng, J., Cheng, F. W. T., Leung, A. W. K., Lee, V., Yeung, E. W., Lam, H. C., Cheung, J., Lam, G., Chow, T. T. W., Yan, C. L., et al. (2020) · Pediatric Investigation · doi:10.1002/ped4.12216 · Cited by 13
“In addition to the survival benefit associated with improved end-induction response, following highdose chemotherapy, surgical resection, auto-HSCT and radiation therapy, anti-GD2 immunotherapy was shown in several studies to have superior survival when compared with standard therapy with isotretinoin alone in high-ri…”
ResultWithycombe, J. S., Carlson, A., Coleman, C. L., Leslie, S., Skeens, M. A., Tseitlin, H., & Duffy, E. A. (2020) · Journal of Pediatric Oncology Nursing · doi:10.1177/1043454220966590 · Cited by 11
Yeku, O., & Longo, D. L. (2023) · New England Journal of Medicine · doi:10.1056/nejme2300317 · Cited by 11
Kailayangiri, S., Altvater, B., Farwick, N., Meltzer, J., Hartmann, W., & Rössig, C. (2024) · STAR Protocols · doi:10.1016/j.xpro.2024.103199 · Cited by 13
Kushner, B. H., Modak, S. I., Mauguen, A., Basu, E. M., Kramer, K., Roberts, S. S., Cheung, I. Y., & Cheung, N. V. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3427 · Cited by 10
Metadata
- Authors
- Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., Shimada, H., Grupp, S. A., Seeger, R., Reynolds, C. P., Buxton, A., Reisfeld, R. A., Gillies, S. D., Cohn, S. L., Maris, J. M., & Sondel, P. M.
- Affiliations
- University of California San Diego (US)
- Levine Children's Hospital (US)
- Boston Children's Hospital (US)
- Duke Medical Center (US)
- National Institutes of Health (US)
- University of Southern California (US)
- University of California, San Francisco (US)
- Children's Hospital of Philadelphia (US)
- Texas Tech University (US)
- Children's Oncology Group (US)
- Scripps Research Institute (US)
- University of Chicago (US)
- University of Wisconsin–Madison (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-30
- Volume
- 363
- Issue
- 14
- Pages
- 1324-1334
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3086629
- OpenAlex
- W2130465135
- Cited by
- 1,835
- References
- 38
- Citations by year
- 2026: 99 · 2025: 98 · 2024: 124 · 2023: 133 · 2022: 142 · 2021: 151 · 2020: 156 · 2019: 107 · 2018: 107 · 2017: 139 · 2016: 105 · 2015: 115 · 2014: 95 · 2013: 103 · 2012: 92
- FWCI
- 49.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (CA98543)
- U.S. Food and Drug Administration (FD-R-002319)
- National Cancer Institute (CA‐98413, U10 CA-98413, U10-CA98543, U10CA098413, R01CA032685, U10CA29139, U10CA029139, U10CA098543, CA-98543)
- Topics
- Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- neuroblastoma, GD2, GM-CSF, interleukin-2, isotretinoin, immunotherapy, high-risk neuroblastoma, event-free survival, overall survival, disialoganglioside, stem cell transplantation, multimodal therapy
- MeSH terms
- Antibodies, Monoclonal, Antineoplastic Agents, Child, Child, Preschool, Combined Modality Therapy, Drug Therapy, Combination, Gangliosides, Humans, Immunotherapy, Infant, Interleukin-2, Neuroblastoma, Isotretinoin, Survival Analysis, Granulocyte-Macrophage Colony-Stimulating Factor, Stem Cell Transplantation, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.